Comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 vs 14q11 2 Microduplication Syndrome C4749855
Clinical comparison between 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 and 14q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
14q11 2 Microduplication Syndrome C4749855
A rare genetic condition involving a small extra piece of chromosome 14. Features vary and may include developmental delays. Management focuses on supportive therapies and monitoring.
6 comparison axes
Onset
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
14q11 2 Microduplication Syndrome C4749855
0-5
Onset patterns differ
Severity
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
14q11 2 Microduplication Syndrome C4749855
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
14q11 2 Microduplication Syndrome C4749855
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
14q11 2 Microduplication Syndrome C4749855
No
Different transmission
Body System
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
14q11 2 Microduplication Syndrome C4749855
congenital
Same/different system
Category
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
14q11 2 Microduplication Syndrome C4749855
genetic
Different category
Bottom line
17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 and 14q11-2-microduplication-syndrome-C4749855 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 14q11 2 Microduplication Syndrome C4749855 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension is described and may begin in childhood or adolescence. | Hypertension is not an established feature in the supplied description. | Moderate |
| Puberty and genital development | Ambiguous genitalia and absent puberty are described. | These endocrine findings are not established for this chromosomal condition. | High |
| Development | Developmental delay is not a defining feature in the supplied description. | Features vary and may include developmental delay. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Hypertension with disordered puberty or ambiguous genitalia
This pattern fits the described steroid-hormone disorder better than the chromosomal description.
Moderate
Suspected adrenal steroid-synthesis abnormality
The left condition is categorized as an endocrine disorder affecting steroid production.
High
Need for lifelong hormone replacement is being considered
Replacement is described for the left condition, but the regimen must be clinician-directed.
Moderate
Choose 14q11 2 Microduplication Syndrome C4749855 when
Early developmental concerns without a clear endocrine pattern
The right condition is described as variable and may include developmental delay.
Low
Chromosomal microarray suggests extra 14q11.2 material
A confirmed duplication would support the chromosomal diagnosis over the endocrine disorder.
High
Congenital multisystem features need supportive planning
Management is described as supportive therapy and monitoring rather than hormone replacement.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 14q11 2 Microduplication Syndrome C4749855 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Abnormal steroid production is expected, but exact cutoffs are not supplied. | No characteristic steroid abnormality is established here. | Interpret only with specialist endocrine review; an abnormal result is not itself a diagnosis. |
| Chromosomal microarray | A 14q11.2 duplication is not the described cause. | May identify a small extra segment at 14q11.2. | Genetic confirmation and clinical correlation are required. |
| Blood pressure monitoring | Hypertension may be present and needs follow-up. | No specific blood-pressure pattern is established. | Measurement supports assessment but does not distinguish the conditions alone. |
Prognosis comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- A severe chronic endocrine condition is described; individual outcome is not established here.
- Factors
- Blood-pressure control, hormone management, and puberty-related care may influence course.
14q11 2 Microduplication Syndrome C4749855
- Outcome
- A moderate chronic congenital condition with variable features is described.
- Factors
- Developmental profile and access to supportive therapies may shape needs.
Time frame: Both may be recognized in childhood, with the duplication often considered by age 5.
No mortality, prevalence, or universal prognosis is established by the supplied data.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related risk | High blood pressure is described and may require long-term monitoring. Not established from the supplied source. Do not infer cardiovascular outcomes without individual assessment. |
| Pubertal or reproductive effects | Absent puberty and genital ambiguity are described. Not established in the supplied description. Counseling should be individualized by specialists. |
| Developmental needs | Not a primary described feature. Developmental delay may occur and features vary widely. Supportive therapies are guided by observed needs, not a fixed course. |
Patient education highlights
- HighSpecialist confirmation
Both are rare; diagnosis requires appropriate endocrine or genetic testing and clinician interpretation.
- HighTreatment approach
The steroid disorder is described as needing lifelong hormone replacement; the duplication is managed supportively.
- MediumVariable course
Reported features do not predict every person's symptoms, severity, or long-term outcome.